Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Quarterly Sales
Fierce Pharma
Astellas lifts forecast as Vyloy surge counters trial miss
Alongside a recorded loss pinned on Vyloy's pancreatic cancer setback, Astellas also terminated ASP4396, a phase 1 KRAS G12D program.
Angus Liu
Feb 5, 2026 11:00am
Fierce Pharma
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
WuXi AppTec posts sales decline but picks up new business in Q3
Oct 29, 2024 8:25am
Abbott clings to billion-dollar COVID test sales a little longer
Jul 20, 2022 11:37am
Dexcom keeps up the pace as it plots global CGM launches
Apr 29, 2022 11:47am
Hologic M&A to pick up slack from future COVID testing declines
Apr 28, 2022 12:30pm
